144 related articles for article (PubMed ID: 38478219)
1. Transcriptome analysis of an AKT inhibitor-resistant endometrial cancer cell line.
Onishi T; Takashima T; Shibahara K; Takagi S; Tanaka S; Mori M; Odashima H; Osawa Y; Hattori M
Pharmacol Rep; 2024 Apr; 76(2):379-389. PubMed ID: 38478219
[TBL] [Abstract][Full Text] [Related]
2. MicroRNA-29b Inhibits Angiogenesis by Targeting VEGFA through the MAPK/ERK and PI3K/Akt Signaling Pathways in Endometrial Carcinoma.
Chen HX; Xu XX; Tan BZ; Zhang Z; Zhou XD
Cell Physiol Biochem; 2017; 41(3):933-946. PubMed ID: 28222438
[TBL] [Abstract][Full Text] [Related]
3. Identification of six candidate genes for endometrial carcinoma by bioinformatics analysis.
Zhu Y; Shi L; Chen P; Zhang Y; Zhu T
World J Surg Oncol; 2020 Jul; 18(1):161. PubMed ID: 32641130
[TBL] [Abstract][Full Text] [Related]
4. Transcriptome Profiling of Cisplatin Resistance in Triple-negative Breast Cancer: New Insight into the Role of PI3k/Akt Pathway.
Memar M; Farazmandfar T; Sabaghian A; Shahbazi M; Golalipour M
Curr Mol Med; 2023; 23(6):559-568. PubMed ID: 35585821
[TBL] [Abstract][Full Text] [Related]
5. Akt inhibitors MK-2206 and nelfinavir overcome mTOR inhibitor resistance in diffuse large B-cell lymphoma.
Petrich AM; Leshchenko V; Kuo PY; Xia B; Thirukonda VK; Ulahannan N; Gordon S; Fazzari MJ; Ye BH; Sparano JA; Parekh S
Clin Cancer Res; 2012 May; 18(9):2534-44. PubMed ID: 22338016
[TBL] [Abstract][Full Text] [Related]
6. Transcriptomic identification of differentially expressed genes in Levonorgestrel resistant endometrial cancer cell lines.
Dore M; Faya N; Filoche S; Henry C
Mol Carcinog; 2023 Jul; 62(7):1038-1050. PubMed ID: 37067396
[TBL] [Abstract][Full Text] [Related]
7. Acquired AKT-inhibitor Resistance Is Mediated by ATP-binding Cassette Transporters in Endometrial Carcinoma.
Takagi S; Onishi T; Takashima T; Shibahara K; Mori M
Anticancer Res; 2023 Jun; 43(6):2501-2507. PubMed ID: 37247888
[TBL] [Abstract][Full Text] [Related]
8. JQ1 suppresses tumor growth via PTEN/PI3K/AKT pathway in endometrial cancer.
Qiu H; Li J; Clark LH; Jackson AL; Zhang L; Guo H; Kilgore JE; Gehrig PA; Zhou C; Bae-Jump VL
Oncotarget; 2016 Oct; 7(41):66809-66821. PubMed ID: 27572308
[TBL] [Abstract][Full Text] [Related]
9. Long non-coding RNA LINP1 functions as an oncogene in endometrial cancer progression by regulating the PI3K/AKT signaling pathway.
Zhang XH; Li M; Kang YJ; Xie YQ; Cao YX
Eur Rev Med Pharmacol Sci; 2019 Aug; 23(16):6830-6838. PubMed ID: 31486482
[TBL] [Abstract][Full Text] [Related]
10. MiR-101 reduces cell proliferation and invasion and enhances apoptosis in endometrial cancer via regulating PI3K/Akt/mTOR.
Zhang S; Wang M; Li Q; Zhu P
Cancer Biomark; 2017 Dec; 21(1):179-186. PubMed ID: 29081412
[TBL] [Abstract][Full Text] [Related]
11. MiR-210-3p accelerates tumor-relevant cell functions of endometrial carcinoma by repressing RUNX1T1.
Dai Z; Luo H; Chen J; Li L
Mutat Res; 2022; 825():111793. PubMed ID: 35963185
[TBL] [Abstract][Full Text] [Related]
12. Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.
Shoji K; Oda K; Kashiyama T; Ikeda Y; Nakagawa S; Sone K; Miyamoto Y; Hiraike H; Tanikawa M; Miyasaka A; Koso T; Matsumoto Y; Wada-Hiraike O; Kawana K; Kuramoto H; McCormick F; Aburatani H; Yano T; Kozuma S; Taketani Y
PLoS One; 2012; 7(5):e37431. PubMed ID: 22662154
[TBL] [Abstract][Full Text] [Related]
13. Molecular alterations of PI3K/Akt/mTOR pathway: a therapeutic target in endometrial cancer.
Pavlidou A; Vlahos NF
ScientificWorldJournal; 2014; 2014():709736. PubMed ID: 24526917
[TBL] [Abstract][Full Text] [Related]
14. Suppression of PI3K/Akt/mTOR/c-Myc/mtp53 Positive Feedback Loop Induces Cell Cycle Arrest by Dual PI3K/mTOR Inhibitor PQR309 in Endometrial Cancer Cell Lines.
Hsin IL; Shen HP; Chang HY; Ko JL; Wang PH
Cells; 2021 Oct; 10(11):. PubMed ID: 34831139
[TBL] [Abstract][Full Text] [Related]
15. Ginkgolic acid induces apoptosis and autophagy of endometrial carcinoma cells via inhibiting PI3K/Akt/mTOR pathway in vivo and in vitro.
Zhou L; Li S; Sun J
Hum Exp Toxicol; 2021 Dec; 40(12):2156-2164. PubMed ID: 34132136
[TBL] [Abstract][Full Text] [Related]
16. Heat Shock Protein B7 Inhibits the Progression of Endometrial Carcinoma by Inhibiting PI3K/AKT/mTOR Pathway.
Xing M; Wu B; Wang S
Reprod Sci; 2023 Feb; 30(2):590-600. PubMed ID: 35859224
[TBL] [Abstract][Full Text] [Related]
17. Integrated Analysis of Hub Genes and Pathways In Esophageal Carcinoma Based on NCBI's Gene Expression Omnibus (GEO) Database: A Bioinformatics Analysis.
Yu-Jing T; Wen-Jing T; Biao T
Med Sci Monit; 2020 Aug; 26():e923934. PubMed ID: 32756534
[TBL] [Abstract][Full Text] [Related]
18. Inhibiting the PI3K/Akt pathway reversed progestin resistance in endometrial cancer.
Gu C; Zhang Z; Yu Y; Liu Y; Zhao F; Yin L; Feng Y; Chen X
Cancer Sci; 2011 Mar; 102(3):557-64. PubMed ID: 21205080
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway but not the MEK/ERK pathway attenuates laminin-mediated small cell lung cancer cellular survival and resistance to imatinib mesylate or chemotherapy.
Tsurutani J; West KA; Sayyah J; Gills JJ; Dennis PA
Cancer Res; 2005 Sep; 65(18):8423-32. PubMed ID: 16166321
[TBL] [Abstract][Full Text] [Related]
20. Fucoxanthin prevents cell growth and induces apoptosis in endometrial cancer HEC-1A cells by the inhibition of the PI3K/Akt/mTOR pathway.
Qu J; Sun Y; Yang L; Niu X; Li L
J Biochem Mol Toxicol; 2022 Jun; 36(6):e23027. PubMed ID: 35266250
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
